METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS

The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not a...

Full description

Saved in:
Bibliographic Details
Main Authors WEBER, ALFRED, TESCHNER, WOLFGANG, HOFBAUER, LUCIA, BAUER, THERESA, BUTTERWECK, HARALD ARNO, SCHWARZ, HANS-PETER
Format Patent
LanguageEnglish
French
Published 18.09.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti- brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies), are also provided. La présente invention concerne, entre autres, des procédés de fabrication de compositions d'immunoglobulines G d'origine plasmatique hautement enrichies en anticorps protéiques associés à une maladie du cerveau (par ex., des anticorps anti- , anti-RAGE, et anti-α-synucléine). De manière avantageuse, les procédés selon l'invention n'affectent pas les processus de fabrication ou les capacités de production d'agents thérapeutiques à base d'IgG d'origine plasmatique. L'invention concerne également des compositions d'IgG d'origine plasmatique qui sont hautement enrichies en anticorps protéiques associés à une maladie du cerveau (par ex., des anticorps anti- , anti-RAGE, et anti-α-synucléine). L'invention concerne également des méthodes pour le traitement de maladies et de troubles du cerveau par administration de compositions d'IgG d'origine plasmatique hautement enrichies en anticorps protéiques associés à une maladie du cerveau (par ex., des anticorps anti- , anti-RAGE, et anti-α-synucléine).
Bibliography:Application Number: WO2014US28953